Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31734841 | 0.88 | ADORA3 (0.56) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL31734837 | 0.87 | ADORA3 (0.56) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL31734833 | 0.87 | ADORA3 (0.78) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL20180024 | 0.86 | ADORA3 (0.72) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL22206535 | 0.85 | NT5E (0.76) | ADORA3ADORA1ADORA2ANT5E | |
| SCHEMBL22215078 | 0.84 | NT5E (0.65) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL20180090 | 0.84 | ADORA3 (0.61) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL20180026 | 0.83 | ADORA3 (0.61) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL22214992 | 0.82 | NT5E (0.62) | ADORA3ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL17213520 | 0.81 | ADORA1 (0.54) | ADORA3ADORA1ADORA2AADORA2BNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361261-A1 | CYCLOPENTYL ADENOSINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SHANGHAI SENHUI MEDICINE CO LTD (CN) | 2025-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361261-A1 | CYCLOPENTYL ADENOSINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA1 2/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.